Skip to content. | Skip to navigation

European Coalition on Homeopathic & Anthroposophic Medicinal Products


Antimicrobial resistance

Antimicrobial Resistance (AMR) is the ability of microorganisms to resist antimicrobial treatments, especially antibiotics. It features high on the EU health policy agenda as it has a direct impact on human and animal health - due to the failure in the treatment of infectious diseases – and carries a huge economic cost. AMR is the result of excessive and inappropriate use of antimicrobial medicines on humans and animals and poor infection control practices and should be considered a serious public health threat across the globe. According to the Commission, 25,000 people die in the EU each year from an infection due to antibiotic-resistant bacteria. If the current trend is not altered, 300 million people worldwide are expected to die prematurely because of drug resistance over the next 35 years.

In 2011,  the EU put in place an Action Programme on AMR which consists of 12 areas of action under two main headings:

  • Educating citizens and prescribers on the proper use of antibiotic treatment
  • Promotion of Research and Development for new and more effective antibiotics.

The potential role of homeopathic and anthroposophic medicine

ECHAMP believes that homeopathic and anthroposophic medicinal products can make a major contribution to addressing the issues and challenges posed by AMR, as research clearly shows that homeopathy can serve as an effective alternative to antibiotics in a range of infectious conditions for which they have been commonly used.

A Joint Statement, issued by ECHAMP, ECH, ECCH and ECPM in response to the Commission Action Programme underlines that homeopathy may be at least as effective as conventional treatment in treating certain infectious diseases. It could therefore serve as an effective first line option in treating viral and mild bacterial infectious diseases and so help preserve antibiotics for when they are really needed.

As the latest discussions in relation to the revision of the legal EU framework for veterinary medicinal products show, this view is slowly gaining support amongst EU-level policy makers, particularly in the European Parliament.

Related content

Last updated on 11 Aug 2016